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Abstract
Introduction  The beneficial effects of ACE inhibitors are generally ascribed 
to blockade of neurohormonal activation. However, especially in chronic heart 
failure patients plasma angiotensin II and aldosterone levels can be elevated 
despite ACE inhibition, the so-called ACE escape. In the present study, we aimed 
to identify the frequency and determinants of ACE escape in CHF patients. 
Methods  We studied 99 stable chronic heart failure patients (NYHA class III 
and IV, 66% ischemic etiology) receiving long-term therapy with ACE inhibitors. 
In all patients, cardiac, renal, and neurohormonal parameters were measured. 
ACE escape was defined as plasma angiotensin level ≥16 pmol/L. 
Results   Mean (± SD) left ventricular ejection fraction of our 99 patients (79 men 
and 20 women, age 69 ± 12 years) was 28 ± 10%. In addition to an ACE inhibitor, 
93% of patients received diuretics, 71% a β-blocker, and 49% spironolactone. 
None of the patients used an angiotensin receptor blocker. In our population, 
45% of the patients had an angiotensin II plasma concentration higher than 16 
pmol/L (median concentration was 14.1 pmol/L). Spironolactone use was an 
independent predictor of elevated plasma angiotensin II levels. Furthermore, 
spironolactone users had significantly higher plasma active renin protein and 
aldosterone levels. Plasma angiotensin II concentration was positively correlated 
to active renin, plasma angiotensin I and plasma aldosterone. No correlation 
was found between plasma angiotensin II levels and serum ACE activity, dose of 
ACE inhibitor, or duration of use. 
Conclusion  In a group of severe chronic heart failure patients, 45% had 
elevated plasma angiotensin II levels independent of serum ACE activity despite 
long-term ACE inhibitor use. Although a causal link could not be proven, an 
association was found between spironolactone use and active renin protein, 
angiotensin II and aldosterone levels, suggesting that escape from ACE is mainly 
caused by a feedback mechanism. 
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Introduction
Inhibition of the renin angiotensin system with angiotensin-converting enzyme 
(ACE) inhibitors proved to be beneficial in patients with chronic heart failure 
(CHF).1;2 The clinically favorable outcome of CHF patients using an ACE 
inhibitor is mainly explained by reduction of angiotensin II formation. However, 
in patients on chronic ACE inhibition the angiotensin II and aldosterone levels 
will often rise again, even though plasma ACE levels remain suppressed and 
the antihypertensive effect does not disappear.3-6 Escape from ACE inhibition 
occurs particularly in patients with an activated renin angiotensin system 
(RAS). Activation of the RAS depends on several factors such as medication, 
salt intake, physical activity, posture and genetic preposition.7-9 In addition, 
activation of the RAS is observed in CHF patients and in these patients the 
activity is related to the severity of CHF. Plasma angiotensin II levels under 
ACE inhibition vary from less than 10 pg/ml in mild CHF patients to 70 pg/ml in 
patients with severe CHF.10;11 Angiotensin II has been viewed as a primary factor 
causing target organ damage in the cardiovascular system, and aldosterone 
exacerbates its tissue-damaging properties.12;13 Moreover, both elevated 
angiotensin II concentrations and elevated plasma aldosterone levels are 
associated with poorer prognosis.14;15  
However, predictors of ACE and aldosterone escape have not been well 
described. Therefore, the present study was designed to measure plasma 
angiotensin II levels and other neurohormones in heart failure patients on 
chronic ACE inhibitor therapy in a routine clinical setting, and to identify which 
factors are related to ACE escape.  
 
Methods
Between February 2003 and November 2003, we evaluated 106 patients with 
congestive heart failure New York Heart Association (NYHA) functional class 
III or IV, as a result of idiopathic dilated cardiomyopathy, ischemic or valvular 
heart disease, who presented at the Heart Failure Clinic of St. Antonius Hospital 
(Nieuwegein), University Hospital Groningen (Groningen), and Deventer 
Hospital (Deventer). All had been followed by the outpatient clinic of one of 
the participating hospitals and all subjects were being treated with stable 
doses of ACE inhibitor for at least three months. Diagnosis had been made on 
the basis of medical history, ongoing symptoms and physical examination. All 
patients had a left ventricular ejection fraction (LVEF) <45%, as assessed by 
echocardiography or radionucleotide measurement. Every patient had been in 
a stable clinical condition for at least three months before the study. 
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Patients who used an angiotensin II receptor blocker were excluded from this 
study. Various ACE inhibitors were used and the dose of each ACE inhibitor was 
expressed as a percentage of the maximum recommended dose (Table 1).16 
The study was approved by each hospital’s ethics committee and written 
informed consent was obtained from all patients.
Hormonal measurements 
Venous blood samples and urine samples were taken at the outpatient clinic 
while the patient was in an upright position. The blood and urine samples 
were transported to the local laboratory immediately, and each aliquot was 
processed and stored according to protocol for later batched analysis. The 
concentration of aldosterone was measured by a sandwich radioimmunoassay 
(Diagnostic Products Corporation, Breda, the Netherlands). Active renin 
protein was measured by an immunoradiometric assay (Nichols Institute 
Diagnostics, Middlesex, United Kingdom) and serum ACE activity was measured 
by an enzymatic assay (Bühlmann Laboratory AG, Schünenbuch, Switzerland). 
Analyses were performed in a routine setting according to the guidelines of the 
manufacturer. Angiotensin I and II were measured by specific radioimmunoassays 
after SepPak extraction of plasma as described previously.17 ACE escape was 
defined as an angiotensin II plasma concentration of ≥16 pmol/L (≥16.7 pg/ml), 
which is twice the upper limit of the reference value used in our laboratory, 
and comparable to the definition used by Roig et al.14
NT-probrain natriuretic peptide (NTproBNP) was measured by an Elecsys NT-
proBNP immunoassay (Roche Diagnostics, Mannheim, Germany). 
 Angiotensin II < 16 pmol/L Angiotensin II ≥ 16 pmol/L Significance
  (n = 54)  (n = 45)                     (two-tailed)
      p-value
Captopril (%, mdd) 27.8 (94 mg) 15.7 (59 mg) <0.001*
Enalapril (%, mdd) 33.1 (18 mg) 37.8 (13 mg) 0.677*
Fosinopril (%, mdd) 1.9 (10 mg) 6.7 (23 mg) 0.327*
Lisinopril (%, mdd) 27.8 (13 mg) 20.0 (15 mg) 0.481*
Perinodpril (%, mdd) 3.7 (2 mg) 17.8 (3.7 mg) 0.040*
Quinapril (%, mmd) 5.6 (23 mg) 2.2 (30 mg) 0.624*
Dose ACE-inhibitor
(% of recommended daily dose) 72 ± 37 68 ± 37 0.568#
Duration of ACE-i use (months) 46 ± 28 36 ± 30 0.110#
Table 1. ACE-inhibitor characteristics 
# independent samples t-test, * chi-square test 
Abbreviations: MDD, median daily dose
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Statistics 
Values are expressed as mean values ± SD, and neurohormone levels or activity 
are expressed as median values (25th-75th percentile). Differences between 
groups were investigated by using the unpaired t-test for independent samples 
and the chi-square test, when appropriate. Stepwise multiple regression 
analysis was performed to identify the independent predictors of increased 
plasma angiotensin II levels. Neurohormonal data were log-transformed before 
statistical comparison in order to correct for skewness. Linear and logistic 
regression analysis were performed to identify relations between variables. A 
p-value <0.05 was considered statistically significant. 
Results
Of the 106 patients in our study, seven patients were excluded because they 
either failed to give informed consent (n=2), because inadequate venous 
blood samples were collected (n=3), or because the LVEF was higher than 45% 
(n=2). Therefore, the study population consisted of 99 patients (age 68.5 ± 
11.7 years), 65 of whom had ischemic heart disease, 14 had a dilated cardio-
myopathy, and the remaining patients had CHF due to other causes. Ninety-
four patients (95%) were in NYHA functional class III and 5 patients were in 
functional class IV. Mean daily dose of captopril, enalapril, and lisinopril were 
82.9 mg, 15.2 mg, and 13.9 mg respectively (Table 1). Detailed patient char-
acteristics are listed in Table 2. Despite chronic ACE inhibitor treatment, 45 
patients (45%) had plasma angiotensin II levels ≥16 pmol/L (median 35.4 pmol/
L), while levels were within normal range in the remaining 54 patients (me-
dian 7.7 pmol/L). The variables in Table 2 with a significance level of p<0.10 
in the univariate tests were age, LVEF, spironolactone use, and systolic blood 
pressure. These values were included into a multivariate model. Multivariate 
analysis identified only spironolactone use and dose to be related to elevated 
plasma angiotensin II levels (p= 0.020). Patients on spironolactone had signifi-
cantly higher levels of angiotensin II (40.5 vs. 16.5 pmol/L, p<0.001, Figure 1) 
and of aldosterone (755.9 vs. 491.2 pmol/L, p=0.005, Figure 1) compared to 
patients not using spironolactone. Of the patients on spironolactone 60% had 
elevated angiotensin II levels (versus 31% in non-users, p=0.005), while 54% had 
aldosterone >650 pmol/L (versus 17% in non-users, p<0.001). Potassium levels 
were comparable in both spironolactone users and non-users (4.4 ± 0.4 mmol/L 
versus 4.5 ± 0.5 mmol/L). Median plasma levels of neurohormones are listed 
in Table 3. Correlations were found between plasma angiotensin II levels and 
active renin protein (r=0.574, p<0.001), plasma angiotensin I level (r=0.445, 
p<0.001), and plasma aldosterone level (r=0.337, p=0.016). No significant 
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 Angiotensin II < 16 pmol/L Angiotensin II ≥ 16 pmol/L Significance
  (n = 54)  (n = 45)                     (two-tailed)
      p-value
Sex male (%) 78.8 82.2 0.583*
 female (%) 22.2 17.8 
Age (years) 70.5 ± 10.0 66.0 ± 13.3 0.055#
Body mass index (kg/m2) 27.6 ± 4.6 27.8 ± 4.5 0.859#
ACE inhibitor (%) 100.0 100.0 
Beta Blocker 75.9 64.4 0.211*
Diuretic 90.7 95.6 0.352*
Spironolactone 35.2 64.4 0.004*
 Dose (mg/day) 20.6 26.2 0.039#
Anti arrhythmic 11.1 15.6 0.514*
Calcium Blocker 11.1 13.3 0.565*
Acetyl salicylic acid 24.1 22.2 0.966*
Oral anticoagulant 68.7 68.9 0.972*
Digoxin  20.4 24.4 0.627*
Ischemic cause (%) 66.7 64.6 0.817*
Diabete  No 72.2 72.3 
   Type 1 0 6.7 0.121*
   Type 2 27.8 20.0 
Smoking No 85.2 85.1 0.647*
   Yes 14.8 14.9
Blood pressure (mm Hg)
   Diastolic 76 ± 11 74 ± 10 0.303#
   Systolic 126 ± 19 119 ± 22 0.089#
LVEF  (%)  30 ± 10 26 ± 10 0.074#
Hemoglobine (mmol/L) 8.4 ± 0.8 8.6 ± 0.7 0.311#
Cholesterol (mmol/L) 4.66 ± 1.06 4.93 ± 0.98 0.217#
AF or flutter (%) 16.7 15.6 0.887*
cGFR (ml/min)a 60.0 ± 22.9 64.4 ± 23.8 0.670#
Diet
  Fluid restriction 24.1 26.7 0.768*
  Low sodium 59.3 57.8 0.882*
 
Table 2. Patient characteristics
a Glomerular filtration rate calculated using the Cockroft-Gault equation
# independent samples t-test * chi-square test
Abbreviations: AF, atrial fibrillation; LVEF, left ventricular ejection fraction
correlation was found with serum ACE activity (r=-0.036, p = 0.755, Table 4). 
Furthermore, no significant correlation was found between plasma angiotensin 
II levels and plasma NT-proBNP levels, or duration of ACE inhibitor use, while a 
weak association was found with LVEF (r=-0.243, p=0.019).  Subgroup analyses 
demonstrated that the 22 patients receiving captopril had higher serum ACE 
activity than the patients using another ACE inhibitor (68.2 U/L vs. 18.7 U/L, 
p<0.001). However, the frequency of ACE escape tended to be lower in these 
patients (32% versus 49%, p=0.145).
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Discussion
In the present study, we evaluated 99 patients with severe CHF who used an 
ACE inhibitor for at least three months. We found that 45 patients (45%) had 
elevated angiotensin II levels despite the long-term use of an ACE inhibitor. 
No clinical characteristic was found to be related to ACE escape. The use of 
a non-selective aldosterone antagonist was the only predictor of elevated 
angiotensin II levels. Moreover, elevated plasma angiotensin II levels were 
related to increased active renin protein and plasma angiotensin I levels. A 
previous study suggested that betablockers reduce the activity of the renin 
angiotensin system.18 Our data support this suggestion (Figure 2).
 Angiotensin II < 16 pmol/L Angiotensin II ≥ 16 pmol/L p-value
     (two-tailed)
Angiotensin II (pmol/L) 7.7 (4.3-11.2) 35.4 (2.5-61.5) <0.001#
Angiotensin I (pmol/L) 618 (264-1377) 2358 (881-5137) <0.001#
Active renin (µU/mL)) 138 (53-299) 770 (260-2400) <0.001#
ACE activity (U/L) 15.8 (12.6-22.0) 16.5 (11.6-20.9) 0.627# µ
Aldosterone (pmol/L)  385 (200-585) 690 (390-1135)   0.001#
NT-proBNP 111.4 (50.0-236.9) 128.0 (50.5-281.9) 0.624#
Table 3. Median neurohormonal levels (25th-75th percentile) 
# independent samples t-test, µ captopril users excluded 
It is firmly established that ACE inhibitor use does not completely block 
angiotensin II and aldosterone production, and in some patients, angiotensin II 
and aldosterone levels remain high.3;10;14;19 This might be the result of insufficient 
suppression of ACE due to an inadequate dose of ACE inhibitor. The most obvious 
explanation for this ACE escape is the existence of alternative enzymes for the 
formation of angiotensin II.20 Non-ACE mediated pathways (e.g. tissue chymase 
mediated angiotensin II formation) may become activated when the activity of 
ACE is reduced by an ACE inhibitor. 
Remarkably, in our study ACE escape was not affected by either dose or duration 
of ACE inhibitor use, or with serum ACE activity. In a previous study it was 
suggested that during storage captopril dissociates from ACE, which might lead 
to an overestimation of serum ACE activity, whereas other studies suggested 
that captopril is not able to suppress the activity of ACE as profoundly as 
other ACE inhibitors.21;22 Therefore, in the present study captopril users were 
excluded from analyses involving serum ACE activity. Active renin protein and 
angiotensin I levels were elevated in the patients with elevated angiotensin 
II levels. It has been well described that renin and angiotensin I accumulate 
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during short-term and long-term ACE inhibition.23-25 Since all our patients had 
been on a steady dose of ACE inhibitor for at least three months, this does not 
account for the different hormone levels we found in our population. 
Particularly in patients that used spironolactone, plasma angiotensin II and 
aldosterone levels were elevated. In addition, these patients had higher plasma 
levels of active renin protein and angiotensin I. These results indicate that 
blockade of the aldosterone receptor on top of ACE inhibition in CHF patients 
induces further activation of the renin angiotensin system, likely through 
intensification of  the positive renin feedback mechanism (Figure 3). Due to 
activation of renin and increased availability of angiotensin I, more angiotensin 
II and aldosterone will be formed. The activity of ACE seems to be of minor 
importance in this process. 
Our data are consistent with the results of Rousseau et al. who performed 
a neurohormonal substudy in the RALES population.26;27 Fifty-four patients 
on spironolactone had significantly higher plasma angiotensin II levels and 
plasma aldosterone levels after three and six months of treatment, than 53 
patients who were treated with placebo. In their study 97.2% of the patients 
received an ACE inhibitor. After 48 months of follow-up cardiac mortality in the 
spironolactone group was significantly lower (21% vs. 38%, p=0.05) than in the 
placebo group. They suggested that the mechanism underlying the Angiotensin 
II and aldosterone escape reflected activated feedback mechanisms on the 























Figure 1. Plasma concentrations of active renin protein, angiotensin II, and aldosterone in patients 
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with the conclusion drawn by Roig et al.14 They identified a group of patients 
with  increased levels of angiotensin II within a selected group of patients using 
ACE inhibitors, and compared this group to the patients with normal levels 
of angiotensin II. Both groups had similar left ventricular ejection fractions 
and no patients used spironolactone. After 3 years, death or new heart failure 
episodes occurred in 43 % of the patients with increased angiotensin II levels at 
baseline, compared with 13 % of the patients with normal angiotensin II levels 
(p=0.002). Therefore, Roig et al. stated that beside a marker for the severity 
of heart failure, an increased plasma angiotensin II level under ACE inhibition is 
an independent predictor for increased mortality and morbidity in heart failure 
patients as well.14 Patients using spironolactone appear to be an exception to 























Figure 2. Comparison of angiotensin II plasma levels in severe CHF according to medication profile 
Abbreviations: BB, betablocker; spiro, spironolactone
Recently, beneficial effects were described of angiotensin receptor blockers in 
combination with ACE inhibitors in CHF patients in the CHARM-trial.29 Although 
in CHARM no subgroup analysis was performed, we hypothesize that especially 
CHF patients with elevated plasma angiotensin II and plasma aldosterone levels 
despite ACE inhibitor use might benefit from additional treatment aimed at 
receptor blockade within the RAS. Both angiotensin receptor blockers and 
aldosterone receptor blockers are candidates for neutralizing the detrimental 
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Figure 3.  Hypothesis: A: negative renin feedback of angiotensin II in untreated patients. B: positive 
renin feedback (or lack of negative feedback?) when only ACE is blocked, resulting from lower 
angiotensin II levels; C: intensified renin feedback when both ACE and aldosterone receptors are 
blocked.  
Limitations
This was an observational, hypothesis-generating study in an out-patient clinical 
setting. Consequently, analysis revealed a wide variety of neurohormonal 
concentrations. This might be due to different levels of activation of the RAS 
under the circumstances we used. However, we believe that for revealing 
mechanisms within the RAS in a population-based study, it is a valuable tool. 
Secondly, the cut-off values for plasma angiotensin II concentrations were 
partly arbitrary. The cut-off value of 16 pmol/L is comparable to the value 
used by by Roig et al.14 Approximately half of their patients escaped from 
ACE inhibitor therapy and had elevated plasma angiotensin II levels, which is 
comparable to the percentage (45%) we found. Finally, we did find different 
daily doses of individual ACE inhibitors in both groups (Table 1). However, when 
all ACE inhibitors were grouped the mean dose (expressed as percentage of the 
recommended dose) was not statistically different. Consequently, we cannot 





































Parameter A Parameter B Pearson r p-value
 
Dose  Log (ACE-activity)* 0.112 0.277
Log (angiotensin II) Dose 0.027 0.794
Log (ACE-activity)* Log (angiostenin II)                 -0.036 0.755   
Table 4. Correlation between ACE inhibitor dose, ACE activity and angiotensin II levels
* captopril users excluded
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Conclusion
In a group of severe chronic heart failure patients 45% had elevated plasma 
angiotensin II levels despite long-term ACE inhibitor use. Elevated levels were 
associated with the use of spironolactone, and with increased levels of active 
renin protein and angiotensin I. No association was found between angiotensin 
II levels and serum ACE activity, or dose or duration of ACE inhibitor use. 
Therefore, we believe ACE escape is related to a feedback mechanism, leading 
to increased levels of active renin protein and angiotensin I. This mechanism is 
intensified when patients use both an ACE inhibitor and an aldosterone receptor 
antagonist. 
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